bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-71-3427

Order Name:
Tempus xT panel (HRD + PD-L1 + MMR + TO), tissue (FFPE) + Blood **

 
Useful For:
To help dentify treatment options tailored for the individual cancer patient.
Tempus targeted gene panel focused on actionable mutations by DNA sequencing, and Full transcriptome by RNA sequencing. Plus PD-L1 testing. Plus HRD testing. Plus MMR testing. Plus TO testing.
 
Methodology:
DNA sequencing using tumor/normal match
RNA sequencing (Whole transcriptome RNA sequencing with validated fusion detection)
IHC for PD-L1 (22C3, and/or 28-8, and/or SP142)
DNA-based test for HRD
IHC for MMR (DNA mismatch repair protein panel)
NGS Database analyse from RNA expression results for TUO (Tempus Tumor Origin)
 
Test List In Profile:
xT-648 gene panel
RNA expression
PD-L1 
HRD
MMR
TO (TUO) tumor of unknown origin
 
AliasesName:
xT Solid Tumor + PD-L1 + HRD + MMR + TUO
 
 
 
Test Code:
090-71-3427

Order Name:
Tempus xT panel (HRD + PD-L1 + MMR + TO), tissue (FFPE) + Blood **

 
Collection Specimen Or Container:
FFPE tissue block (at least 20% tumor) + H&E slide(optional)
+ Blood (Tempus Kit) - Two 10mL Streck tubes, sending ASAP

Document Required
- Filled Requisition Form & Sign Consent 
- Pathology report
- Progress note
 
Specimen Testing Type:
10 FFPE unstained slides for NGS, 5 um sections on positivelt charged, un baked slides**
1   Terminal H&E stained slide
6   FFPE unstained slides for DNA mismatch repair protein panel IHC (MMR)
3   FFPE unstained slides for PD-L1 IHC
+ Whole blood 10mL Streck x 2 tubes 

**Submit 10 additional slides if tissue is <25 mm2
 
Sub Mission Container:
Tempus tissue collection Kit  +  Tempus blood collection Kit
 
 
Specimen Stabillity:
Specimen Type Temperature Time
Whole blood Ambient temperature 7 days *
* Sent to USA
 
 
 
Test Code:
090-71-3427

Order Name:
Tempus xT panel (HRD + PD-L1 + MMR + TO), tissue (FFPE) + Blood **

 
Method detail:
DNA sequencing using tumor/normal match
RNA sequencing (Whole transcriptome RNA sequencing with validated fusion detection)
IHC for PD-L1 (22C3, and/or 28-8, and/or SP142)
DNA-based test for HRD
IHC for MMR (DNA mismatch repair protein panel)
NGS Database analyse from RNA expression results for TUO (Tempus Tumor Origin)
 
Schedule:
N/A **Sent out to Ontarget Medicine Co, Ltd. (Tempus, USA).
 
 
Turnaround Time:
Received specimen to reported within 4-5 weeks (Slide received to report)
 
Performing Location:
Ontarget Medicine Co, Ltd. (Tempus, USA).
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-71-3427

Order Name:
Tempus xT panel (HRD + PD-L1 + MMR + TO), tissue (FFPE) + Blood **

 
 
Clinical Information:
These tests can predict which patients are at higher risk, and therefore might benefit from adjuvant therapy, as well as other endpoints that can positively impact a patient’s journey.

HRD TEST
The Tempus Homologous Recombination Deficiency (HRD) test is a DNA-based test, available as part of the xT platform, for clinicians aiming to better understand if their patient has Homologous Recombination Deficiency. Tempus HRD is a comprehensive view into a patient’s ability to repair double-stranded DNA breaks. HRD status can be used to identify patients who may be sensitive to PARP inhibitors and/or platinum-based chemotherapy.

The Tempus HRD test takes into account results from our xT Sequencing Panel, giving a full view into 18 commonly mutated genes in the HR-pathway, along with a genome wide loss-of-heterozygosity (LOH) score, giving a clinician one of the most complete views of HRD status on the market. The HRD test can be ordered with 6 major cancer subtypes: Ovarian, Breast, Pancreatic, Prostate, Non-small-cell lung cancer, and Glioblastoma, and does not require additional tissue from the patient.

TUO TEST
The Tempus Tumor Origin (TO) test uses information from analysis of nucleic acids by next-generation sequencing (NGS) performed as part of a separately-ordered Tempus|xT test. The Tempus TO test was built using a large internal database of annotated tumor molecular data. The TO test uses tumor RNA expression results to indicate the most likely primary cancer subtype and other potentially likely subtypes of a tumor specimen from 64 possible diagnostic subtypes.

The intended use of the TO test is for cancers of unknown primary (CUPs) and other tumors of uncertain origin and may help clinicians make more informed decisions where other clinical information like imaging and immunohistochemistry results do not provide a definitive diagnosis. 

When paired with xT,  the TO results may provide insight into the tumor’s diagnosis and site of origin that may be used to guide patient care and clinical trial eligibility.
 
Interpretation:
Tempus reports associate potentially relevant therapies with detected genomic alterations and prioritize them based on the strength of the clinical evidence.
 
Clinical Reference:
www.tempus.com (Retrieved: 5 Mar 2021)